Fixed dose combination dextromethorphan-bupropion: A hope for treatment resistant depression (TRD)

Background: Treatment resistant depression (TRD) has been identified as non-response to depression with adequate dose and trial of two antidepressant medications of different classes. Near about 30% depressive patients are TRD cases. Olanzapine‐fluoxetine combination, rTMS, Intravenous ketamine and...

Full description

Saved in:
Bibliographic Details
Main Authors: Ranjan Das, Rajarshi Chakravarty, Varaha V. Gantait, Subir Bhattacharjee
Format: Article
Language:English
Published: Wolters Kluwer Medknow Publications 2025-06-01
Series:Indian Journal of Psychiatry
Subjects:
Online Access:https://journals.lww.com/10.4103/indianjpsychiatry_315_25
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Background: Treatment resistant depression (TRD) has been identified as non-response to depression with adequate dose and trial of two antidepressant medications of different classes. Near about 30% depressive patients are TRD cases. Olanzapine‐fluoxetine combination, rTMS, Intravenous ketamine and Electroconvulsive therapy have been till now studied in TRD. Dextromethorphan-bupropion is a newer antidepressant, which has been found to be effective, fast-acting, and well tolerated medicine for depression. Cases and conclusion: We used this novel antidepressant in three cases of TRD, alone and with combination, and it showed satisfactory response within 2 weeks.
ISSN:0019-5545
1998-3794